Treatment of benign prostatic hyperplasia

Rev Assoc Med Bras (1992). 2017 Feb;63(2):95-99. doi: 10.1590/1806-9282.63.02.95.
No abstract available

Publication types

  • Guideline

MeSH terms

  • 5-alpha Reductase Inhibitors / therapeutic use
  • Adrenergic alpha-Antagonists / therapeutic use
  • Adrenergic beta-3 Receptor Agonists / therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Lower Urinary Tract Symptoms / drug therapy*
  • Lower Urinary Tract Symptoms / etiology
  • Lower Urinary Tract Symptoms / prevention & control
  • Male
  • Muscarinic Antagonists / therapeutic use
  • Phosphodiesterase 5 Inhibitors / therapeutic use
  • Phytotherapy
  • Prostatic Hyperplasia / complications
  • Prostatic Hyperplasia / drug therapy*
  • Prostatic Hyperplasia / prevention & control
  • Quality of Life

Substances

  • 5-alpha Reductase Inhibitors
  • Adrenergic alpha-Antagonists
  • Adrenergic beta-3 Receptor Agonists
  • Muscarinic Antagonists
  • Phosphodiesterase 5 Inhibitors